Patents by Inventor Kesavaram Narkunan

Kesavaram Narkunan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180155386
    Abstract: Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
    Type: Application
    Filed: December 4, 2017
    Publication date: June 7, 2018
    Inventors: Klaus Nickisch, Kesavaram Narkunan, Baishakhi Debnath, Bindu Santhamma
  • Patent number: 8673968
    Abstract: Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: March 18, 2014
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, James Cessac, Kesavaram Narkunan, Baishakhi Das
  • Publication number: 20130029953
    Abstract: Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
    Type: Application
    Filed: July 28, 2011
    Publication date: January 31, 2013
    Inventors: Klaus Nickisch, Kesavaram Narkunan, Baishakhi Debnath, Bindu Santhamma
  • Patent number: 8222237
    Abstract: Described herein are 3-(6,6-ethylene-17?-hydroxy-3-oxo-17?-pregna-4-ene-17?-yl)propionic acid ?-lactone derivatives having progestational and aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: July 17, 2012
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Pemmaraju Rao, Kesavaram Narkunan, James Cessac
  • Publication number: 20100273759
    Abstract: Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.
    Type: Application
    Filed: March 29, 2010
    Publication date: October 28, 2010
    Inventors: Klaus Nickisch, James Cessac, Kesavaram Narkunan, Baishakhi Das
  • Patent number: 7777060
    Abstract: Disclosed herein are novel platinum-based analogs possessing two nitrile substituent groups (bis-nitrile) covalently-bonded to the platinum. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as quantitative in vitro IC50 data.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: August 17, 2010
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventors: Xinghai Chen, Pavankumar N. V. Petluru, Qiuli Huang, Kesavaram Narkunan, Frederick Hausheer
  • Publication number: 20100137264
    Abstract: Described herein are 3-(6,6-ethylene-17?-hydroxy-3-oxo-17?-pregna-4-ene-17?-yl)propionic acid ?-lactone derivatives having progestational and aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.
    Type: Application
    Filed: November 25, 2009
    Publication date: June 3, 2010
    Inventors: Klaus Nickisch, Pemmaraju Rao, Kesavaram Narkunan, James Cessac
  • Patent number: 7687496
    Abstract: The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: March 30, 2010
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventors: Kesavaram Narkunan, Xinghai Chen, Harry Kochat, Frederick Hausheer
  • Patent number: 7687497
    Abstract: The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: March 30, 2010
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventors: Kesavaram Narkunan, Xinghai Chen, Harry Kochat, Frederick Hausheer
  • Publication number: 20090099224
    Abstract: The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).
    Type: Application
    Filed: October 16, 2007
    Publication date: April 16, 2009
    Inventors: Kesavaram Narkunan, Xinghai Chen, Harry Kochat, Frederick Hausheer
  • Publication number: 20090099166
    Abstract: The novel C10-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B-ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).
    Type: Application
    Filed: October 16, 2007
    Publication date: April 16, 2009
    Inventors: Kesavaram Narkunan, Xinghai Chen, Harry Kochat, Frederick Hausheer
  • Publication number: 20080194680
    Abstract: Disclosed herein are novel platinum-based analogs possessing two nitrile substituent groups (bis-nitrile) covalently-bonded to the platinum. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as quantitative in vitro IC50 data.
    Type: Application
    Filed: October 30, 2007
    Publication date: August 14, 2008
    Inventors: Xinghai Chen, Pavankumar N.V. Petluru, Qiuli Huang, Kesavaram Narkunan, Frederick Hausheer
  • Publication number: 20060094876
    Abstract: A process for synthesizing highly lipophilic derivatives of camptothecin. The process includes reacting dissolved, underivatized camptothecin with a silylated heterocyclic compound in a modified Minisci-type alkylation reaction to produce 7-substituted derivatives of camptothecin.
    Type: Application
    Filed: October 28, 2004
    Publication date: May 4, 2006
    Inventors: Ye Wu, Kesavaram Narkunan, Jianyan Wang, Harry Kochat
  • Patent number: 7030243
    Abstract: A process for synthesizing highly lipophilic derivatives of camptothecin. The process includes reacting dissolved, underivatized camptothecin with a silylated heterocyclic compound in a modified Minisci-type alkylation reaction to produce 7-substituted derivatives of camptothecin.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: April 18, 2006
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventors: Ye Wu, Kesavaram Narkunan, Jianyan Wang, Harry Kochat
  • Patent number: 6723849
    Abstract: A process for synthesizing highly lipophilic derivatives of camptothecin. The process includes reacting dissolved, underivatized camptothecin with an aldehyde in a modified Minisci-type alkylation reaction to produce 7-substituted derivatives of camptothecin.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: April 20, 2004
    Assignee: BioNumerik Pharmaceuticals, Inc.
    Inventors: Kesavaram Narkunan, Harry Kochat, Xinghai Chen